&lt;title&gt;Photodynamic therapy for the prevention of restenosis after angioplasty&lt;/title&gt;

Asahara, Takayuki; Usui, Mikio; Amemiya, Takashi; Oike, Yasuhisa; Shiraishi, Hiromori; Miyagi, Manabu; Nakajima, Hitoshi; Kato, Tomitsugu; Naito, Yuichi; Ibukiyama, Chiharu

doi:10.1117/12.146574

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Photofrin was able to diminish intimal hyperplasia 1 week after endothelial injury. The same observation, 1 to 2 weeks after endothelial injury, was established by Asahara et al [40] in their rabbit model when using hematoporphyrin. A study from Hsiang et al [41,42] emphasizes the fact that photodynamic therapy after intimal injury should be given within the first week after endothelial injury, before significant intimal hyperplasia has occurred.…”

Section: Photodynamic Therapy For Intimal Hyperplasiasupporting

confidence: 73%

See 1 more Smart Citation

Photodynamic therapy for atherosclerosis. The potential of indocyanine green

Houthoofd¹,

Vuylsteke

Mordon

et al. 2020

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

The aim of this article is to summarize and review the use of photodynamic therapy for the treatment of atherosclerotic plaque and the prevention of intimal hyperplasia. Different photosensitizers are discussed and more specific the role of indocyanine green as a potential photosensitizer. Methods: Literature search with focus on the use of photodynamic therapy in atherosclerosis, the mechanism of action and the different photosensitizers for photodynamic therapy. Results: In-vitro and in-vivo studies confirm the use of photodynamic therapy for the treatment of atherosclerosis and the prevention of restenosis. Non-specific accumulation of photosensitizer and thus phototoxicity, remains an important problem. Indocyanine green is a photosensitizer with features in favor of photodynamic therapy. The results of photodynamic therapy with indocyanine green point towards the potential of indocyanine green as a photosensitizer in photodynamic therapy for atherosclerosis. Conclusion: Photodynamic therapy is a promising tool for atherosclerosis. Many of the studied photosensitizers have toxic effects. Indocyanine green might be a good photosensitizer for the use of photodynamic therapy in atherosclerosis. These data justify further research to the use of indocyanine green as a photosensitizer in the treatment of atherosclerotic plaque both de novo or in restenotic lesions.

show abstract

Section: Photodynamic Therapy For Intimal Hyperplasiasupporting

confidence: 73%

“…In vivo studies were performed in different animal models like rats, rabbits, swine and monkey [34][35][36][37][38][39][40][41][42]. They all have promising results concerning the use of photodynamic therapy but show great variety in optimal dose of used photosensitizer, time interval and used light source.…”

Section: Photodynamic Therapy For Intimal Hyperplasiamentioning

confidence: 99%

Photodynamic therapy for atherosclerosis. The potential of indocyanine green

Houthoofd¹,

Vuylsteke

Mordon

et al. 2020

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

show abstract

“…There have been few reports on the efficacy of PDT in the treatment of atheroma, [11][12][13][14][15][16][17][18][19][20][21][22][23] and we were unable to find any reports using the YAG-OPO laser. In this present study we conducted PDT using the YAG-OPO laser in an intravascular approach on atherosclerotic rabbit aortas, investigating the regression effect on hypertrophic intima.…”

contrasting

confidence: 40%

Photodynamic Therapy of Atherosclerosis Using YAG-OPO Laser and Porfimer Sodium, and Comparison With Using Argon-Dye Laser

et al. 1999

Self Cite

View full text Add to dashboard Cite

We performed photodynamic therapy (PDT) using the Yttrium Aluminium Garnet-Optical Parametric Oscillated (YAG-OPO) laser in cases of atherosclerosis, and examined its efficacy in vivo. We also performed PDT using an Argon-dye (Ar-dye) laser with the same output, and compared the efficacies. Following balloon denudation injury of the thoracoabdominal aorta, rabbits were raised on a cholesterol diet for 16 weeks, producing atheroma in that region. At 24 h following the administration of Photofrin 5 mg/kg, PDT was performed, and animals were sacrificed at 1 day, 1 week, and 2 weeks following the procedure to examine its efficacy. This was compared with the efficacy of PDT using the Ar-dye laser. Following PDT using a YAG-OPO laser, an increase in the vessel lumen was seen due to reduction of the hypertrophic intima and media, without the appearance of inflammatory cells. This result was seen more strongly in PDT using the pulse wave YAG-OPO laser than with the continuous wave Ar-dye laser, affecting not just the intima but also the media. These data demonstrated that PDT can effectively regress atherosclerotic lesions. (Jpn Circ J 1999; 63: 288 -295)

show abstract

“…It was reported that there was comparatively more effect against SMC obtained from atherosclerotic lesions than those from nonatherosclerotic sites [15,16]. Thus it is suggested that HpD accumulation is related to the synthetic phenotype of SMC [17].…”

Section: Hpd Accumulationmentioning

confidence: 96%